Guy Goodwin
Professor of Psychiatry
Data updated
Research Footprint
Guy Goodwin appears in 16 tracked papers (2017–2026), most studied alongside Psilocybin, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Ekaterina Malievskaia, Lindsey Marwood and Namik Kirlic.
Publication Landscape
How the 16 papers Blossom tracks for Guy Goodwin line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Guy Goodwin's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 16 of 16 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Guy Goodwin publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Guy Goodwin publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Guy M. Goodwin is a senior British psychiatrist and academic with a longstanding research career in affective disorders, psychopharmacology and clinical trials. Historically recognised for work on mood disorders and bipolar depression, he has in recent years been a prominent clinical investigator and co‑author on multiple studies examining therapeutic applications of psilocybin — including single‑dose treatment for treatment‑resistant major depressive episodes, long‑term observational follow‑up after psilocybin treatment, and safety and tolerability investigations in post‑traumatic stress disorder. He has also contributed to work on psychological support models for COMP360 psilocybin therapy and to novel analytic approaches such as using natural language processing to predict clinical outcomes.
Goodwin’s contributions bridge traditional psychiatric therapeutics and emerging psychedelic‑assisted therapies: he participates in multidisciplinary trials, authors methodological guidance for psychedelic research, and collaborates with leading groups in the field (including colleagues such as Robin Carhart‑Harris and Scott T. Aaronson). His emphasis remains on rigorous safety evaluation, clinical outcome measurement and integration of psychopharmacological knowledge into the design and interpretation of psychedelic therapy studies.
Key Impact
A senior psychiatrist and clinical researcher who has helped translate classical affective‑disorder psychopharmacology expertise into contemporary clinical trials of psilocybin therapy, including single‑dose treatment studies and safety evaluations.
Collaboration Network
32 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Guy Goodwin's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Guy Goodwin is associated with.
University of Oxford Department of Psychiatry
The Department of Psychiatry at the University of Oxford is a clinical department within the Medical Sciences Division that conducts research, teaching, and clinical trials across psychiatry, neuroscience, and mental health. It is based at the Warneford Hospital site in Oxford, England.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways plc (Nasdaq: CMPS) is a UK-headquartered clinical-stage biopharmaceutical company and the most advanced developer of a classic psychedelic medicine. Its lead asset, COMP360 — a synthetic, proprietary formulation of psilocybin — is being developed for treatment-resistant depression (TRD) delivered alongside a psychological-support model. COMP360 is the first psilocybin programme to complete two positive pivotal Phase 3 trials: COMP005 met its primary endpoint in June 2025 and the confirmatory COMP006 (two fixed doses given three weeks apart) did so in February 2026, with 26-week data reported in July 2026 confirming a rapid and durable antidepressant profile. In April 2026 the FDA granted a rolling NDA submission request and selected COMP360 for the Commissioner's National Priority Voucher programme, which carries a shortened review window. COMPASS has since begun that rolling submission and guides to a potential US launch in the first half of 2027, subject to approval, positioning it as the frontrunner for the first FDA-approved classic psychedelic therapy.
View stakeholder →